DEFA14A: Protagenic Therapeutics and Phytanix Bio Announce Merger, Creating Neuroactive Biopharmaceutical Firm

Protagenic Therapeutics and Phytanix Bio combine in an all-stock transaction to form Phytanix, Inc., a neuroactive biopharmaceutical company with a diverse pipeline.

Summary

• Protagenic Therapeutics, Inc. (PTIX) and Phytanix Bio Inc. have merged in an all-stock transaction, forming Phytanix, Inc.
• The combined entity will focus on stress-related and CNS disorders, with a pipeline of six drug candidates.
• Key assets include PT-00114 (Phase I/IIa), PHYX-001, and multiple cannabinoid-based compounds targeting CNS, cardiometabolic, and obesity indications.
• Under the share exchange agreement, Protagenic issued 117,690 shares of common stock, 5,705 shares of Series C preferred stock, and 950,000 shares of Series C-1 preferred stock to Phytanix Bio stockholders.
• Additionally, 20,000 shares of Series D preferred stock and warrants to purchase up to 715,493 shares of common stock were issued to Phytanix Bio's preferred stockholders.
• Post-combination ownership is approximately 35% for pre-combination PTIX stockholders and 65% for Phytanix Bio stockholders on a fully diluted basis.
• Stockholder approval is required for the conversion of preferred stock and exercise of warrants issued in the combination, in compliance with Nasdaq rules.
• The merger aims to leverage complementary assets and expertise to address unmet needs in neuropsychiatry and CNS disorders.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the benefits of pipeline expansion, diversity, and expertise. The management comments are optimistic, and the structure of the combination appears well-defined.

Positives

• The merger expands Protagenic's pipeline with new CNS programs.
• The combined entity has a diverse pipeline with clinicaland preclinical-stage assets.
• The merger integrates CNS expertise from Phytanix Bio team members.
• The combined company has a broader composition-of-matter patent coverage across the pipeline.
• The merger combines talent pools to advance development and regulatory activities.

Risks

• The press release contains forward-looking statements that are subject to substantial risks and uncertainties.
• Actual results may differ materially from those indicated by forward-looking statements due to various factors.
• The company specifically disclaims any intention to update any forward-looking statements included in the press release.

Future Outlook

The combined entity, Phytanix, Inc., will focus on advancing its pipeline of assets to address unmet needs in neuropsychiatry, CNS, and other disorders. The company anticipates significant milestones over the next 18 months.

Management Comments

• Garo H. Armen, PhD, Executive Chairman, stated that the combination aligns two pipelines with complementary assets and expertise.
• Barrett Evans, President and Chief Executive Officer, expressed excitement about uniting the teams and advancing programs for patients and shareholders.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and expertise to create more robust pipelines and address unmet medical needs, particularly in high-growth areas like CNS disorders and metabolic diseases where GLP-1 agonists have seen success.

Comparison to Industry Standards

• The pipeline assets, particularly the potassium channel modulator PHYX-001, are comparable to XEN1101 (Xenon Pharmaceuticals) and BHV-7000 (Biohaven), which are also potassium channel modulators targeting neurological disorders.
• The cannabinoid assets are similar to those developed by GW Pharma (Sativex and Epidiolex), indicating a focus on innovative medicines manufactured from cannabinoid and cannabinoid-like molecules.
• The combination of two companies with complementary assets and expertise is a common strategy in the biopharmaceutical industry to create a more robust and diversified pipeline, similar to mergers and acquisitions seen among larger pharmaceutical companies.

Management Changes

Stakeholder Impact

• Shareholders of Protagenic Therapeutics will benefit from the expanded pipeline and potential milestones.
• Patients may benefit from the development of new treatments for neuropsychiatry, CNS, and other disorders.
• Employees of both companies will be integrated into a combined team.

Next Steps

• Obtain stockholder approval for the conversion of preferred stock and exercise of warrants.
• Advance the development of pipeline assets, including PT-00114 and PHYX-001.
• Integrate the teams and expertise of Protagenic Therapeutics and Phytanix Bio.

Key Dates

Keywords

merger, acquisition, biopharmaceutical, cannabinoid, neuroactive, phytanix, protagenic, therapeutics, pipeline, CNS, obesity, metabolic, disorders